1. Home
  2. ALX vs CDNA Comparison

ALX vs CDNA Comparison

Compare ALX & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alexander's Inc.

ALX

Alexander's Inc.

N/A

Current Price

$250.27

Market Cap

1.1B

Sector

Real Estate

ML Signal

N/A

Logo CareDx Inc.

CDNA

CareDx Inc.

N/A

Current Price

$16.54

Market Cap

1.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ALX
CDNA
Founded
1928
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Medical Specialities
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.0B
IPO Year
1994
2007

Fundamental Metrics

Financial Performance
Metric
ALX
CDNA
Price
$250.27
$16.54
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$27.33
AVG Volume (30 Days)
56.7K
551.4K
Earning Date
01-01-0001
05-13-2026
Dividend Yield
7.32%
N/A
EPS Growth
N/A
N/A
EPS
5.50
N/A
Revenue
$213,183,000.00
$48,324,000.00
Revenue This Year
N/A
$15.37
Revenue Next Year
N/A
$11.23
P/E Ratio
$44.72
N/A
Revenue Growth
N/A
18.93
52 Week Low
$189.05
$10.96
52 Week High
$260.84
$21.49

Technical Indicators

Market Signals
Indicator
ALX
CDNA
Relative Strength Index (RSI) 61.29 31.50
Support Level $229.52 $14.09
Resistance Level $260.04 $17.09
Average True Range (ATR) 8.12 0.83
MACD 1.02 -0.23
Stochastic Oscillator 89.87 4.91

Price Performance

Historical Comparison
ALX
CDNA

About ALX Alexander's Inc.

Alexander's Inc is a real estate investment trust engaged in leasing, managing, developing and redeveloping its properties. It has six properties in the greater New York City metropolitan area. All of the revenues come from properties located in New York City which include revenues from leasing of space to tenants at their properties and revenues from parking and tenant services.

About CDNA CareDx Inc.

CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.

Share on Social Networks: